

DAFTAR PUSTAKA

- Abdelrahman, A. E., Rashed, H. E., Abdelgawad, M., & Abdelhamid, M. I. (2017, Jun). Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer. *Ann Diagn Pathol*, 28: 43-53.
- Abubakar, Mustapha, Changyuan, G., Koka, H., Hyuna, S., Nan, S., *et al.* (2019). Clinicopathological and Epidemiological Significance of Breast Cancer Subtype Reclassification Based on P53 Immunohistochemical Expression. *Npj Breast Cancer*, 5(1):20.
- Adams, S., Diamond, J. R., Hamilton, E. P., Pohlmann, P. R., Tolaney, S. M., *et al.* (2016, May). Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). *J Clin Oncol*, 34(suppl): abstr 1009.
- Adams, S., Loi, S., Toppmeyer, D., Cescon, D. W., Laurentiis, M. D., Nanda, R., *et al.* (2017, May). Phase 2 study of pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B. *Clin Oncol*, 35(suppl 15): abstr 1088.
- Aghili, M., Lashkari, M., Farrokhpey, A.H., and Izadi, S. (2013). Triple-Negative Breast Cancer Survival in Iranian Patients. *Acta Med Iran*, 51(8):560-66.
- Agrawal, A., Ziolkowski, P., Grzebieniak, Z., Jelen, M., Bobinski, P., & Agrawal, S. (2016, Sep). Expression of Androgen Receptor in Estrogen Receptor-positive Breast Cancer. *Appl Immunohistochem Mol Morphol*, 24(8): 550-5.
- Ahn, S. G., Kim, S. J., Kim, C., & Jeong, J. (2016). Molecular Classification of Triple-Negative Breast Cancer. *J Breast Cancer*, 19(3): 223-230.
- AiErken, N., Shi, H. J., Zhou, Y., Shao, N., Zhang, J., Shi, Y., *et al.* (2017, Sep). High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients. *Int J Biol Sci*, 13(9): 1172-1179.
- Akwarini, F., Fadjari, T.H., and Hernowo, B.S. (2019). Triple Negative Breast Cancer Characteristics Based on Basal-like and Non-Basal-like Subtypes. *IJIHS*, 7(1):26-33.
- Ali, H.R., Glont, S.E., Blows, F.M., Provenzano, E., Dawson, S.J., Liu, B., *et al.* (2015). PD-L1 Protein Expression in Breast Cancer Is Rare, Enriched in Basal-Like Tumours and Associated With Infiltrating Lymphocytes. *Ann Oncol*, 26(7):1488-93.

- Ali, S., Ahmad, A., Banerjee, S., Padhye, S., Dominiak, K., Schaffert, J.M., *et al.* (2010). Gemcitabine Sensitivity Can Be Induced in Pancreatic Cancer Cells through Modulation of MiR-200 and MiR-21 Expression by Curcumin or Its Analogue CDF. *Cancer Research*, 70(9):3606–17.
- Al Jarroudi, Ouissam, Naima Abda, Youssef Seddik, Sami Aziz Brahmi, and Said Afqir. (2017). Overweight: Is It a Prognostic Factor in Women with Triple-Negative Breast Cancer? *Asian Pacific Journal of Cancer Prevention* 18 (6): 1519-1523.
- Ambros, V. (2001). microRNAs: tiny regulators with great potential. *Cell*, 107(7): 823-6.
- Asangani, I. A., Rasheed, S. A. K., Nikolova, D.A., Leupold, J.H., Colburn, N.H., Post, S., *et al.* (2008). MicroRNA-21 (MiR-21) Post-Transcriptionally Downregulates Tumor Suppressor Pcd4 and Stimulates Invasion, Intravasation and Metastasis in Colorectal Cancer. *Oncogene*, 27(15):2128–36.
- Asano, Y., Kashiwagi, S., Goto, W., Tanaka, S., Morisaki, T., Takashima, T., *et al.* (2017, Jan). Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer. *Onco Targets Ther*, 10: 4675–4685.
- Baffa, R., Fassan, M., Volinia, S., O'Hara, B., Liu, C.G., Palazzo, J.P., *et al.* (2009). MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. *J Pathol*, 219(2):214-21.
- Bai, T., Dong, D.S., Pei, L. (2014). Synergistic antitumor activity of resveratrol and miR-200c in human lung cancer. *Oncol Rep*, 31(5):2293-7.
- Bai, W., Ye, M., Zhang, M., Zhu, H., Xi, W., Huang, X., *et al.* (2014). MiR-200c suppresses TGF- β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer. *Int J Cancer*, 135(6):1356-68
- Baptista, M. Z., Sarian, L. O., Sophie, F. M., Derchain, Pinto, G. A., and Vassallo, J. (2016). Prognostic Significance of PD-L1 and PD-L2 in Breast Cancer. *Human Pathology*, 47(1):78–84.
- Baranwal, S. and Suresh K. A. (2010). MiRNA Control of Tumor Cell Invasion and Metastasis. *Int J Cancer*, 126(6):1283–90.
- Bartel, D. P., & Chen, C. Z. (2004). Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. *Nat Rev Genet*, 5(5): 396-400.
- Bareche, Y., Venet, D., Ignatiadis, M., Aftimos, P., Piccart, M., Rothe, F., Sotiriou, C. (2018). Unravelling Triple-Negative Breast Cancer Molecular

Heterogeneity Using an Integrative Multiomic Analysis. *Ann Oncol*, 29(4):895–920.

Baselga, J., Gómez, P., Greil, R., Braga, S., Climent, M. A., Wardley, A. M., *et al.* (2013, Jul). Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer. *J Clin Oncol*, 31(20): 2586–2592.

Basho, R. K., Gilcrease, M., Murthy, R. K., Helgason, T., Karp, D. D., Meric-Bernstam, F., *et al.* (2017, Apr). Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. *JAMA Oncol*, 3(4): 509-515.

Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A., & Caggiano, V. (2007, May). Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. *Cancer*, 109(9): 1721-8.

Bélembaogo, E., Feillel, V., Chollet, P., Curé, H., Verrelle, P., Kwiatkowski, F., *et al.* (1992). Neoadjuvant chemotherapy in 126 operable breast cancers. *Eur J Cancer*, 28A(4-5): 896-900.

Berber, U., Yilmaz, I., Narli, G., Haholu, A., Kucukodaci, Z., Demirel, D. (2014). miR-205 and miR-200c: Predictive Micro RNAs for Lymph Node Metastasis in Triple Negative Breast Cancer. *J Breast Cancer*, 17(2):143-8.

Bernsdorf, M., Ingvar, C., Jörgensen, L., Tuxen, M. K., Jakobsen, E. H., Saetersdal, A., *et al.* (2011, Apr). Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial. *Breast Cancer Res Treat*, 126(2): 463-70.

Bertoli, G., Cava, C., & Castiglioni, I. (2015, Jul). MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer. *Theranostics*, 5(10): 1122-43.

Bhalla, A., Manjari, M., Kahlon, S. K., Kumar, P., & Kalra, N. (2010, Oct-Dec). Cytokeratin 5/6 expression in benign and malignant breast lesions. *Indian J Pathol Microbiol*, 53(4): 676-80.

Biganzoli, E., Coradini, D., Ambrogi, F., *et al.* (2011). p53 Status Identifies Two Subgroups of Triple-negative Breast Cancers with Distinct Biological Features. *Japanese Journal of Clinical Oncology*, 41(2).

- Blair, Cindy K., Wiggins, C. L., Nibbe, A. M., Storlie, C. B., Prossnitz, E. R., Royce, M.(2019). Obesity and Survival among a Cohort of Breast Cancer Patients Is Partially Mediated by Tumor Characteristics. *Npj Breast Cancer*, 5(1):1–7.
- Bockmeyer, C., Christgen, M., Muller, M., Fischer, S., Ahrens, P., Langer, F., Kreipe, H.(2011). MicroRNA profiles of healthy basal and luminal mammary epithelial cells are distinct and reflected in different breast cancer subtypes. *Breast Cancer Res Treat*.
- Bonadonna, G., Veronesi, U., Brambilla, C., Ferrari, L., Luini, A., Greco, M., *et al.* (1990). Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. *J Natl Cancer Inst*, 82(19): 1539-45.
- Bonnefoi, H., Grellety, T., Tredan, O., Saghatchian, M., Dalenc, F., Mailliez, A., *et al.* (2016, May). A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). *Ann Oncol*, 27(5): 812-8.
- Bonsu, Bemah, A., and Ncama, B. P. (2019). Recognizing and Appraising Symptoms of Breast Cancer as a Reason for Delayed Presentation in Ghanaian Women: A Qualitative Study. *PLoS ONE*, 14(1).
- Børresen-Dale, Anne Lise. (2003). TP53 and Breast Cancer. *Human Mutation*, 21(3):292–300.
- Burk, U., Schubert, J., Wellner, U., Schmalhofer, O., Vincan, E., Spaderna, S., & Brabletz, T. (2008). A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. *EMBO reports*, 9(6), 582–589
- Burstein, M. D., Tsimelzon, A., Poage, G. M., Covington, K. R., Contreras, A., Fuqua, S. A., *et al.* (2015, Apr). Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-negative Breast Cancer. *Clin Cancer Res*, 21(7): 1688–1698.
- Breving, K., & Esquela-Kerscher, A. (2010). The complexities of microRNA regulation: mirandering around the rules. *Int J Biochem Cell Biol*, 42(8): 1316-29.
- Bruce, J. P., & Liu, F. F. (2014). MicroRNAs in nasopharyngeal carcinoma. *Chin J Cancer*, 33(11): 539–544.
- Burstein, M. D., Tsimelzon, A., Poage, G. M., Covington, K. R., Contreras, A., Fuqua, S. A. W., *et al.* (2015). Comprehensive Genomic Analysis

Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer.
Clin Cancer Res, 21(7):1688–98.

- Buscaglia, L. E. and Li, Y. (2011). Apoptosis and the Target Genes of MicroRNA-21. *Chinese Journal of Cancer*, 30(6):371–80.
- Byrski, T., Gronwald, J., Huzarski, T., Grzybowska, E., Budryk, M., Stawicka, M., *et al.* (2009). Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy. *J Clin Oncol*, 28: 375-379.
- Byrski, T., Huzarski, T., Dent, R., Gronwald, J., Zuziak, D., Cybulski, C., *et al.* (2009). Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. *Breast Cancer Res Treat*, 115(2): 359-63.
- Cakar, B., Muslu, U., Erdogan, A. P., Ozisik, M., Ozisik, H., Dalgic, C. T., Durusoy, R., *et al.*. 2015. The Role of Body Mass Index in Triple Negative Breast Cancer. *Oncol Res Treat*, 38(10):518–22.
- Calin, G. A., & Croce, C. M. (2006). MicroRNA signatures in human cancers. *Nat Rev Cancer*, 6(11): 857-66.
- Cardoso, F., Senkus, A., Costa, A., Papadopoulos, E., André, M. a. F., Harbeck, N., *et al.* (2018). 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). *Annals Oncol*, 29(8):1634–57.
- Carey, L. A., Rugo, H. S., Marcom, P. K., Mayer, E. L., Esteva, F. J., Ma, C. X., *et al.* (2012, Jul). TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer. *J Clin Oncol*, 30(21): 2615–2623.
- Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., *et al.* (2007). The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. *Clin Cancer Res*, 13:2329–34.
- Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., *et al.* (2006, Jun). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. *JAMA*, 295(21): 2492-502.
- Carrington, J. C., & Ambros, V. (2003). Role of microRNAs in plant and animal development. *Science*, 301(5631): 336-8.
- Chang, C., Chao, C., Xia, W., Yang, J., Xiong, Y., Li, C., Yu W.(2011). p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs." *Nat Cell Biol* 13(3):317-23.
- Chang, L., Guo, F., Wang, Y., Lv, Y., Huo, B., Wang, L., Liu, W.(2014). MicroRNA-200c regulates the sensitivity of chemotherapy of gastric

cancer SGC7901/DDP cells by directly targeting RhoE. *Pathol Oncol Res* 20(1):93-8.

- Changavi, A. A., Shashikala, A., & Ramji, A. S. (2015, Jul-Dec). Epidermal Growth Factor Receptor Expression in Triple Negative and Nontriple Negative Breast Carcinomas. *J Lab Physicians*, 7(2): 79–83.
- Chavez-MacGregor, Mariana, Clarke, C. A., Lichtensztajn, D. Y., and Giordano, S.H. (2016). Delayed Initiation of Adjuvant Chemotherapy among Patients with Breast Cancer. *JAMA Oncol*, 2(3):322–29.
- Cheang, M. C., Voduc, D., Bajdik, C., Leung, S., McKinney, S., Chia, S. K., *et al.* (2008). Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. *Clin Cancer Res*, 14(5): 1368-76.
- Chintalapani, S., Bala, S., Konatam, M., Gundeti, S., Kuruva, S., Monalisa Hui. (2019). Triple-Negative Breast Cancer: Pattern of Recurrence and Survival Outcomes. *Indian J Med Ped Oncol*, 40(1):67.
- Cho, W. (2010). MicroRNAs: Potential biomarkers for cancer diagnosis, prognosis and targets for therapy. *Int J Biochem Cell Biol*, 42(8), pp.1273-1281.
- Choi, J., Jung, W. H., & Koo, J. S. (2012, Nov). Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers. *Histol Histopathol*, 27(11): 1481-93.
- Choi, Y. L., Oh, E., Park, S., Kim, Y., Park, Y. H., Song, K., Cho, E. Y., Hong, Y. C., Choi, J.S., *et al.* (2010). Triple-Negative, Basal-like, and Quintuple-Negative Breast Cancers: Better Prediction Model for Survival. *BMC Cancer*, 10.
- Choi, Y., Park, S. K., Ahn, K. J., Cho, H., Kim, T. H., Yoon, H. K., *et al.* (2016). Being Overweight or Obese Increases the Risk of Progression in Triple-Negative Breast Cancer after Surgical Resection. *J Korean Med Sci* 31(6):886–91.
- Chottanapund, S., Van Duursen, M. M., Ratchaworapong, K., Navasumrit, P., Ruchirawat, M., & Van den Berg, M. (2016, Sep). Androgen Receptor Expression in Thai Breast Cancer Patients. *Med Sci (Basel)*, 4(3): 15.
- Connolly, E. C., Doorslaer, K., Rogler, L., E., and Rogler, C. E. (2010). Overexpression of MiR-21 Promotes an In Vitro Metastatic Phenotype by Targeting the Tumor Suppressor RHOB. *Molecular Cancer Res*, 8(5):691–700.

- Coradini, D., Biganzoli, E., Ardoino, I., Ambrogi, F., Boracchi, P., Demicheli, R., *et al.* (2015, Jun). p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy. *Breast*, 24(3): 294-7.
- Corkery, B., Crown, J., Clynes, M., & O'Donovan, N. (2009, May). Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. *Ann Oncol*, 20(5): 862-7.
- Corrales, L., Matson, V., Flood, B., Spranger, S., & Gajewski, T. F. (2017). Innate immune signaling and regulation in cancer immunotherapy. *Cell research*, 27(1): 96–108.
- Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., *et al.* (2014). Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet*, 384(9938): 164-72.
- Couch, F. J., Hart, S. N., Sharma, P., Toland, A. E., Wang, X., Miron, P., *et al.* (2015). Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. *J Clin Oncol*, 33(4): 304-11.
- Crozier, J. A., Advani, P. P., LaPlant, B., Hobday, T., Jaslowski, A. J., Moreno-Aspitia, A., & Perez, E. A. (2016, Feb). N0436 (Alliance): A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane-containing therapy. *Clin Breast Cancer*, 16(1): 23–30.
- Dai, X., Xiang, L., Li, T., & Bai, Z. (2016). Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes. *J Cancer*, 7(10): 1281-94.
- Dai, D., Zhong, Y., Wang, Z., Yousafzai, N. A., Jin, H., & Wang, X. (2019). The prognostic impact of age in different molecular subtypes of breast cancer: a population-based study. *Peer J*, 7: e7252.
- Dasari, S., & Tchounwou, P. B. (2014). Cisplatin in cancer therapy: molecular mechanisms of action. *Eur J Pharmacol*, 740: 364-78.
- Davion, S., Sullivan, M., Rohan, S., and Siziopikou, K. P. (2012). P53 Expression in Triple Negative Breast Carcinomas: Evidence of Age-Related and Racial Differences. *J Cancer Therapy*, 03(05):649–54.
- Davis, M., Tripathi, S., Hughley, R., He, Q., Bae, S., Karanam, B., *et al.* (2018, Jun). AR negative triple negative or “quadruple negative” breast cancers in

African American women have an enriched basal and immune signature.
PLoS One, 13(6): e0196909.

de Lint, K., Poell, J. B., Soueidan, H., Jastrzebski, K., Vidal Rodriguez, J., Lieftink, C., *et al.* (2016, Jul). Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R. *Mol Cancer Ther*, 15(7): 1545-56.

Dupont W. D. and Plummer W. D.(1990). Power and sample size calculations: A review and computer program. *Controlled Clinical Trials*, 11:116-28

Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., *et al.* (2015). Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. *J Clin Oncol*, 28(1): 105–113.

Denkert, Loibl, S., Noske, A., Roller, Marc, C., Müller, Berit, M., *et al.* (2010). Tumor-Associated Lymphocytes as an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer. *J Clin Oncol*, 28(1):105–13.

Denkert, C., Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, B. I., Weber, K. E., *et al.* (2018). Tumour-Infiltrating Lymphocytes and Prognosis in Different Subtypes of Breast Cancer: A Pooled Analysis of 3771 Patients Treated with Neoadjuvant Therapy. *Lancet Oncol*, 19(1):40–50.

Denkert, C., von Minckwitz, G., Brase, J. C., Sinn, B. V., Gade, S., Kronenwett, R., *et al.* (2015). Tumor infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor-2 positive and triple-negative primary breast cancers. *J Clin Oncol*, 33: 983–991 .

Dent, R. A., Mainwaring, P. N., Tan, T. J., Barbier, S., Cortes, J., Blackwell, K. L., *et al.* (2015). Survival in Triple-Negative Breast Cancer (TNBC): Evidence from the SEER Database 2010-2011. *J Clin Oncol*, 33(15 suppl):e12075–e12075.

Dent, R., Trudeau, M., Pritchard, K. L., Hanna, W. M., Kahn, H. K., Sawka, C. A., *et al.* (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. *Clin Cancer Res*, 13(15):4429–34.

Ding, Y. C., Steele, L., Warden, C., Wilczynski, S., Mortimer, J., Yuan, Y., and Neuhausen, S. (2019). Molecular Subtypes of Triple-Negative Breast Cancer in Women of Different Race and Ethnicity. *Oncotarget*, 10(2):198–208.

Dogukan, R., Ucak, R., Dogukan, F. M., Tanik, C., Citgez, B., Citgez, B., Kabukcuoglu, F. (2019). Correlation between the Expression of PD-L1 and Clinicopathological Parameters in Triple Negative Breast Cancer Patients. *European Journal of Breast Health*, 15(4): 235–41.

Dogra, A., Doval, D. C., Sardana, M., Chedi, S. K., and Mehta, A. (2014). Clinicopathological Characteristics of Triple Negative Breast Cancer at a Tertiary Care Hospital in India. *Asian Pac J Cancer Prev*, 15(24):10577–83.

Dogra, A., Mehta, A., and Doval, D. C. (2020). Are Basal-Like and Non-Basal-Like Triple-Negative Breast Cancers Really Different? *J Oncol*, 2020.

Dumay, A., Feugeas, J. P., Wittmer, E., Lehmann-Che, J., Bertheau, P., Espié, M., *et al.* (2013). Distinct tumor protein p53 mutants in breast cancer subgroups. *Int J Cancer*, 132(5): 1227-31.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Clarke, M., Coates, A S., Darby, S C., Davies, C., Gelber, R D., Godwin, J., *et al.* (2008). Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. *Lancet*, 371(9606): 29-40.

Etheridge, A., Lee, I., Hood, L., Galas, D., & Wang, K. (2011). Extracellular microRNA: a new source of biomarkers. *Mutat Res*, 717(1-2): 85-90.

El Guerrab, A., Bamdad, M., Kwiatkowski, F., Bignon, Y. J., Penault-Llorca, F., & Aubel, C. (2016, Nov). Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer. *Oncotarget*, 7(45): 73618-73637.

Erturk, E., Cecener, G., Tezcan, G., Egeli, U., Tunca, B., Gokgoz, S., Tolunay, S., Tasdelen, I.(2015). BRCA mutations cause reduction in miR-200c expression in triple negative breast cancer. *Gene*, 556(2):163-9.

Fabris, L., Berton, S., Citron, F., D'Andrea, S., Segatto, I., Nicoloso, M. S., *et al.* (2016). Radiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway. *Oncogene*, 35(37): 4914–4926.

Fang, H., Xie, J., Zhang, M., Zhao, Z., Wan, Y., & Yao, Y. (2017). miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN. *Am J Transl Res*, 9(3): 953–961.

Fayaz, S., Demian, G. A., El-Sherify, M., Eissa, H., Aziz, M., and Abuzallouf, S. (2019). Triple Negative Breast Cancer: 10-Year Survival Update of The Applied Treatment Strategy in Kuwait. *Gulf J Oncolog*, 29:53–59.

- Feng, H., Wang, B., Zhang, Q., Fu, Y., Huang, L., Wang, X., & Kang, Z. (2015). Exploration of microRNAs and their targets engaging in the resistance interaction between wheat and stripe rust. *Front Plant Sci*, 6: 469.
- Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010). Triple-negative breast cancer. *N Engl J Med*, 363(20): 1938-48.
- Frankel, L. B., Christoffersen, N. R., Jacobsen, A., Lindow, M., Krogh, A., & Lund, A. H. (2008). Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. *J Biol Chem*, 283: 1026-33.
- Freedman, G. M., Anderson, P. R., Li, T., & Nicolaou, N. (2009). Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. *Cancer*, 115(5): 946-51.
- Garrido-Castro, A.C., Lin, N. U., and Polyak, K. (2019). Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. *Cancer Discovery*, 9(2):176–98.
- Gatalica, Z., Snyder, C., Maney, T., Ghazalpour, A., Holterman, D. A., Xiao, N., et al. (2014, Dec). Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. *Cancer Epidemiol Biomarkers Prev*, 23(12): 2965-70.
- Gazinska, P., Grigoriadis, A., Brown, J. P., Millis, R. R., Mera, A., Gillett, C. E., et al. (2013). Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles. *Mod Pathol*, 26(7): 955-66.
- Gerdes, J., Schwab, U., Lemke, H., & Stein, H. (1983). Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. *Int J Cancer*, 31(1): 13-20.
- Gerhauser, C.(2013). Epigenetic impact of dietary isothiocyanates in cancer chemoprevention. *Curr Opin Clin Nutr Metab Care*, 16(4):405-10.
- Giordano, S. H., Buzdar, A. U., Smith, T. L., Kau, S. W., Yang, Y., & Hortobagyi, G. N. (2004). Is breast cancer survival improving? *Cancer*, 100(1): 44-52.
- Globocan.iarc.fr. (2012). *Fact Sheets by Population*. Retrieved December Thursday, 2017, from http://globocan.iarc.fr/Pages/fact_sheets_population.aspx
- Gohr, K., Hamacher, A., Engelke, L. H., & Kassack, M. U. (2017, Nov). Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38. *BMC Cancer*, 17(1): 711.

Gonçalves, H., Guerra, M. R., Cintra, J. R. D., Fayer, V. A., Brum, I. V., and Teixeira, M. T. B. (2018). Survival Study of Triple-Negative and Non-Triple-Negative Breast Cancer in a Brazilian Cohort. *Clinical Medicine Insights: Oncology* 12.

Goss, P. E., Strasser-Weippl, K., Lee-Bychkovsky, B. L., Fan, L., Li, J., Chavarri-Guerra, Y., Liedke, P. E., *et al.* (2014). Challenges to Effective Cancer Control in China, India, and Russia. *Lancet Oncol*, 15(5):489–538.

Gralow, J. R., Zujewski, J. A., & Winer, E. (2008). Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions. *J Clin Oncol*, 26(5): 696-7.

Grasselly, C., Denis, M., Bourguignon, A., Talhi, N., Mathe, D., Tourette, A., *et al.* 2018. (The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent. *Frontiers in Immunology* 9(OCT).

Green, D. R., and Chipuk, J. E. (2006). P53 and Metabolism: Inside the TIGAR. *Cell*, 126(1):30–32.

Grünert, S., Jechlinger, M., Beug, H.(2003). Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. *Nat Rev Mol Cell Biol*, 4(8):657-65.

Gucalp, A., Tolaney, S., Isakoff, S. J., Ingle, J. N., Liu, M. C., *et al.* Translational Breast Cancer Research Consortium. (2013, Oct). Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer. *Clin Cancer Res*, 19(19): 5505–5512.

Guo, H., Ingolia, N. T., Weissman, J. S., & Bartel, D. P. (2010). Mammalian microRNAs predominantly act to decrease target mRNA levels. *Nature*, 466(7308): 835-40.

Gu-Trantien, C., Loi, S., Garaud, S., Equeter, C., Libin, M., de Wind, A., *et al.* (2013). CD4+ follicular helper T cell infiltration predicts breast cancer survival. *J Clin Invest*, 123(7): 2873–2892.

Haffty, B. G., Yang, Q., Reiss, M., Kearney, T., Higgins, S. A., Weidhaas, J., *et al.* (2006). Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. *J Clin Oncol*, 24(36): 5652-7.

Hamm, C., Kulkarni, S., Gupta, R., Kay, A., Mathews, J., Hirmiz, K., *et al.* (2016). Early Stage Triple Negative Breast Cancer Has Significantly Better Outcomes than More Advanced Disease: A Single Centre Retrospective Review. *J Cancer Therapy*, 07(10):665–74.

- Hao, S., Liu, Y., Yu, K. D., Chen, S., Yang, W. T., and Shao, Z. M. (2015). Overweight as a Prognostic Factor for Triple-Negative Breast Cancers in Chinese Women. *PLoS ONE*, 10(6):1–10.
- Heeg, E., Mheen, P. J. M., Maaren, M. C. V., Schreuder, K., Tollenaar, R., Siesling, S., *et al.* (2019). Association between Initiation of Adjuvant Chemotherapy beyond 30 Days after Surgery and Overall Survival among Patients with Triple-Negative Breast Cancer. *Int J Cancer*, 69:1–8.
- Herrero-Vicent, C., Guerrero, A., Gavilá, J., Gozalbo, F., Hernández, A., Sandiego, S., *et al.* (2017). Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy. *ecancer*, 11:759.
- Herschkowitz, J., Zhao, W., Zhang, M., Usary, J., Murrow, G., Edwards, D., Knezevic, J.(2012). Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. *Proc Natl Acad Sci U S A*, 109(8):2778-83.
- Hill, L., Browne, G., Tulchinsky, E.(2012). ZEB/miR-200 feedback. *Int J Cancer* 132(4):745-754.
- Hiyoshi, Y., Kamohara, H., Karashima, R., Sato, N., Imamura, Y., Nagai, Y., Yoshida, N., *et al.* (2009). MicroRNA-21 Regulates the Proliferation and Invasion in Esophageal Squamous Cell Carcinoma. *Clin Cancer Res*, 15(6):1915–22.
- Hong, R., Ma, F., Xu, B., Li, Q., Zhang, P., Yuan, P., *et al.* (2014). Efficacy of platinum-based chemotherapy in triple-negative breast cancer patients with metastases confined to the lungs: a single-institute experience. *Anticancer Drugs*, 25(9): 1089-94.
- Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014). Drug resistance in cancer: an overview. *Cancers*, 6(3): 1769–1792.
- Howe, E., Cochrane, D., Richer J.(2011). Targets of miR-200c mediate suppression of cell motility and anoikis resistance. *Breast Cancer Res*. 2011 Apr 18;13(2):R45
- Hugh, J., Hanson, J., Cheang, M. C., Nielsen, T. O., Perou, C. M., Dumontet, C., *et al.* (2009). Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. *J Clin Oncol*, 27(8): 1168-76.

Humphries, B., Wang, Z., Oom, A., Fisher, T., Tan, D., Cui, Y., Jiang, Y., Yang C.(2014). MicroRNA-200b targets protein kinase C α and suppresses triple-negative breast cancer metastasis. *Carcinogenesis* 35(10):2254-63.

Hurley, J., Reis, I., Silva, O., Gomez, C., DeZarraga, F., Velez, P., *et al.* (2005). Weekly docetaxel/carboplatin as primary systemic therapy for HER2-negative locally advanced breast cancer. *Clin Breast Cancer*, 5(6): 447-54.

Isakoff, S. J. (2010). Triple-negative breast cancer: role of specific chemotherapy agents. *Cancer J*, 16(1): 53-61.

Isakoff, S. J., Mayer, E. L., He, L., Traina, T. A., Carey, L. A., Krag, K. J., *et al.* (2015). TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. *J Clin Oncol*, 33(17):1902-9.

Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992, Nov). Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. *EMBO J*, (11): 3887-95.

Johnstone, T. C., Park, G. Y., & Lippard, S. J. (2014). Understanding and improving platinum anticancer drugs--phenanthriplatin. *Anticancer research*, 34(1): 471-476.

Jurmeister, S., Baumann, M., Balwierz, A., Keklikoglou, I., Ward, A., Uhlmann, S., Zhang, J., Wiemann, S., Sahin, Ö.(2012). MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F. *Mol Cell Biol* 32(3):633-51.

Kahraman, M., Röske, A., Laufer, T., Fehlmann, T., Backes, C., *et al.* (2018). MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer. *Sci Rep*, 8: 11584, 8: 11584.

Kalluri, R., Weinberg, R.A. (2009).The basics of epithelial-mesenchymal transition. *J Clin Invest*, 119(6):1420-8.

Kalniete, D., Nakazawa-Miklaševiča, M., Štrumfa, I., Āboliņš, A., Irmejs, A., Gardovskis, J., & Miklaševičs, E. (2015). High expression of miR-214 is associated with a worse disease-specific survival of the triple-negative breast cancer patients. *Hered Cancer Clin Pract*, 13(1): 7. Kanapathy P., Kishen, S., Tay, A., Nair, S., and Leong, C. O. (2012). Triple-Negative Breast Cancer Is Associated with EGFR, CK5/6 and c-KIT Expression in Malaysian Women. *BMC Clin Pathol*, 12(1):1-8.

Kaya, V., Yildirim, M., Yazici, G., Gunduz, S., Bozcuk, H., and Paydas, S. (2018). Effectiveness of Platinum-Based Treatment for Triple Negative Metastatic Breast Cancer: A Meta-Analysis. *Asian Pac J Cancer Prev*, 19(5):1169-73.

Keam, B., Im, S. A., Han, S. W., Han, S. W., Oh, D. Y., Kim, J. H., *et al.* (2011). Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. *Breast Cancer Res, 13*(2): R22.

Keum, N., Greenwood, D. C., Lee, D. H., Kim, R., Aune, D., Ju, W., Hu, F. B., & Giovannucci, E. L. (2015). Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. *Journal of the National Cancer Institute, 107*(2): djv088.

Kim, A., Jang, M. H., Lee, S. J., & Bae, Y. K. (2017, Jun). Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast Cancer. *J Breast Cancer, 20*(2): 150–159.

King, M. C., Marks, J. H., Mandell, J. B., & Group., N. Y. (2003). Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. *Science, 302*(5645): 643-6.

Kodahl, A. R., Zeuthen, P., Binder, H., Knoop, A. S., dan Ditzel, H.J. (2014). Alterations in Circulating MiRNA Levels Following Early-Stage Estrogen Receptor-Positive Breast Cancer Resection in Post-Menopausal Women edited by R. B. Ray. *PLoS ONE, 9*(7):e101950.

Kopp, F., Wagner, E., Roidl, A.(2014). The proto-oncogene KRAS is targeted by miR-200c. *Oncotarget 5*(1):185-95.

Korpai, M., Lee, E.S., Hu, G., Kang, Y.(2008). The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. *J Biol Chem 283*(22):14910-4.

Krichevsky, A. M., & Gabriely, G. (2009). miR-21: a small multifaceted RNA. *J Cell Mol Med, 13*: 39-53.

Kurian, A. W., Fish, K., Shema, S. J., and Clarke, C. A. (2010). Lifetime Risks of Specific Breast Cancer Subtypes among Women in Four Racial/Ethnic Groups. *Breast Cancer Res, 12*(6):R99.

Kurozumi, A., Goto, Y., Matsushita, R., Fukumoto, I., Kato, M., Nishikawa, R., *et al.* (2016). Tumor-suppressive microRNA-223 inhibits cancer cell migration and invasion by targeting ITGA3/ITGB1 signaling in prostate cancer. *Cancer Sci, 107*(1): 84-94.

Kyndi, M., Sørensen, F. B., Knudsen, H., Overgaard, M., Nielsen, H. M., Overgaard, J., & Group, D. B. (2008). Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-

risk breast cancer: the Danish Breast Cancer Cooperative Group. *J Clin Oncol*, 26(9): 1419-26.

Lawler, S. and Chiocca, E. A. (2009). Emerging Functions of MicroRNAs in Glioblastoma. *J Neuro-Oncol*, 92(3 SPEC. ISS.):297–306.

Layman, R. M., Ruppert, A. S., Lynn, M., Mrozek, E., Ramaswamy, B., Lustberg, M. B., *et al.* (2013, May). Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. *Cancer Chemother Pharmacol*, 71(5): 1183-90.

Lee, J. A., Lee, H. Y., Lee, E. S., Kim, I., and Bae, J. W. (2011). Prognostic Implications of MicroRNA-21 Overexpression in Invasive Ductal Carcinomas of the Breast. *J Breast Cancer*, 14(4):269–75.

Lee, M., Park, I. A., Heo, Young A. K., Gyungyub, G., and Hee J. L. (2019). Association between P53 Expression and Amount of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. *J Pathol and Translational Med*, 53(3):180–87.

Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *J Clin Invest*, 121(7): 2750–2767.

Lehmann, B. D., Jovanović, B., Chen, X., Estrada, M. V., Johnson, K. N., Shyr, Y., *et al.* (2016). Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. *PLoS ONE*, 11(6): e0157368.

Lehmann, B. D., Pietenpol, J. A., & Tan, A. R. (2015). Triple-negative breast cancer: molecular subtypes and new targets for therapy. *Am Soc Clin Oncol Educ Book*, e31-9.

Lertkhachonsuk, A., Yip, C. H., Khuhaprema, T., Chen, D. S., Plummer, M., Jee, S. H., *et al.* (2013). Cancer Prevention in Asia: Resource-Stratified Guidelines from the Asian Oncology Summit 2013. *Lancet Oncol*, 14(12).

Li, J., Zhang, X. M., Zhang, Z., Zheng, L., Jindal, S., dan Liu, Y. (2019). Association of P53 Expression with Poor Prognosis in Patients with Triple-Negative Breast Invasive Ductal Carcinoma. *Medicine*, 98(18):e15449.

Li, S., Ma, D., Shi, H. H., Yu, K. D., dan Qiang Zhang. (2018). The Effect of Delayed Adjuvant Chemotherapy on Relapse of Triplenegative Breast Cancer. *J Thorac Dis*, 10(5):2837–41.

Li, T., Li, D., Sha, J., Sun, P., dan Huang, Y. (2009). MicroRNA-21 Directly

Targets MARCKS and Promotes Apoptosis Resistance and Invasion in Prostate Cancer Cells. *Biochem Biophys Res Communications*, 383(3):280–85.

- Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., *et al.* (2008). Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. *J Clin Oncol*, 26(8): 1275.
- Lim, Jeong Uk, Jae Ha Lee, Ju Sang Kim, Yong Il Hwang, Tae-Hyung Kim, Seong Yong Lim, Kwang Ha Yoo, Ki-Suck Jung, Young Kyoon Kim, and Chin Kook Rhee. (2017). Comparison of World Health Organization and Asia-Pacific Body Mass Index Classifications in COPD Patients. *International Journal of COPD* (12): 2465–2475.
- Liu, H., Searle, I. R., Watson-Haigh, N. S., Baumann, U., Mather, D. E., Able, A. J., & Able, J. A. (2015). Genome-Wide Identification of MicroRNAs in Leaves and the Developing Head of Four Durum Genotypes during Water Deficit Stress. *PLoS One*, 10(11): e0142799.
- Livingston-Rosanoff, D., Hanlon, B., Marka, N., Walle, K. V., Stankowski-Drengler, T., Schumacher, J., *et al.* (2019). Time to Initiation of Neo-Adjuvant Chemotherapy for Breast Cancer Treatment Does Not Influence Patient Survival: A Study of US Breast Cancer Patients. *Breast Journal*, 1–5.
- Loi, S., Drubay, D., Adams, S., Pruneri, G., Francis, P.A., Lacroix-Triki, M., *et al.* (2019). Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. *J Clin Oncol*, 37(7):559–69.
- Loi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagalli, D., *et al.* (2014). Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. *Ann Oncol*, 25(8): 1544-50.
- Loi, S., Sirtaine, N., Piette, F., Salgado, R., Salgado, R., Viale, G., Van Eenoo, F., *et al.* (2013). Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin with Doxorubicin-Based Chemotherapy: BIG 02-98. *Journal of Clinical Oncology*, 31(7): 860–67.
- Loibl, S., O’Shaughnessy J., Untch, M., Sikov, W. M., Rugo, H. S., McKee, M. D., Huober, J., Golshan, M., Minckwitz, G., Maag, D., Sullivan, D., *et al.* (2018). Addition of the PARP Inhibitor Veliparib plus Carboplatin or Carboplatin Alone to Standard Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer (BrighTNess): A Randomised, Phase 3 Trial.

Lancet Oncol, 19(4):497–509.

- Lü, L., Mao, X., Shi, P., He, B., Xu, K., Zhang, S., & Wang, J. (2017, Jun). MicroRNAs in the prognosis of triple-negative breast cancer. *Medicine (Baltimore)*, 96(22): e7085.
- Lu, Z., Liu, M., Stribinskis, V., Klinge, C. M., Ramos, K. S., Colburn, N. H., et al. (2008). MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. *Oncogene*, 27: 4373-9.
- MacKenzie, T. A., Schwartz, G. N., Calderone, H. M., Graveel, C. R., Winn, M. E., Hostetter, g., et al. (2014). Stromal Expression of miR-21 Identifies High-Risk Group in Triple-Negative Breast Cancer. *Am J Pathol*, 184(12): 3217–3225.
- Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015, Aug). Combination cancer immunotherapy and new immunomodulatory targets. *Nat Rev Drug Discov*, 14(8): 561-84.
- Maiello, M. R., D'Alessio, A., & Bevilacqua, S. (2015, Dec). EGFR and MEK Blockade in Triple Negative Breast Cancer Cells. *J Cell Biochem*, 116(12): 2778-85.
- Marinello, J., Delcuratolo, M., & Capranico, G. (2018). Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives. *Int J Mol sci*, 19(11): 3480.
- Martin, V., Botta, F., Zanellato, E., Molinari, F., Crippa, S., Mazzucchelli, L., & Frattini, M. (2012, Jun). Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features. *Histol Histopathol*, 27(6): 785-92.
- Masuda, H., Baggerly, K. A., Wang, Y., Zhang, Y., Gonzalez-Angulo, A. M., Meric-Bernstam, F., et al. (2013, Oct). Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. *Clin Cancer Res*, 1: 19(19).
- Masuda, H., Zhang, D., Bartholomeusz, C., Doihara, H., Hortobagyi, G. N., & Ueno, N. T. (2012, Nov). Role of epidermal growth factor receptor in breast cancer. *Breast Cancer Res Treat*, 136(2): 331-45.
- Matikas, A., Zerdes, I., Lövrot, J., Richard, F., Sotiriou, C., Bergh, J., et al. (2019). Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-Analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data. *Clin Cancer Res*, 25(18):5717–26.

Matsumoto, H., Thike, A. A., Li, H., Yeong, J., Koo, S. L., Dent, R. A., Tan, P. H., dan Iqbal, J. (2016). Increased CD4 and CD8-Positive T Cell Infiltrate Signifies Good Prognosis in a Subset of Triple-Negative Breast Cancer. *Breast Cancer Res Treat*, 156(2):237–47.

Mei, L., He, L., Song, Y., Lv, Y., Zhang, L., Hao, F., et al. (2018). Association between Obesity with Disease-Free Survival and Overall Survival in Triple-Negative Breast Cancer A Meta-Analysis. *Medicine*, 97(19):1–7.

Mekala, J. R., Naushad, S. M., Ponnusamy, L., Arivazhagan, G., Sakthiprasad, V., dan Pal-Bhadra, M. (2018). Epigenetic Regulation of MiR-200 as the Potential Strategy for the Therapy against Triple-Negative Breast Cancer. *Gene*, 641:248–58.

Melichar, B., Študentova, H., Kalábová, H., Vitásková, D., Čermáková, P., Hornychová, H., & Ryška, A. (2014). Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy. *Anticancer Res*, 34(3): 1115-25.

Mezquita, B., Mezquita, P., Pau, M., Mezquita, J., Mezquita, C. (2014). Unlocking Doors without Keys: Activation of Src by Truncated C-terminal Intracellular Receptor Tyrosine Kinases Lacking Tyrosine Kinase Activity. *Cells* 3(1):92-111.

Millis, S. Z., Gatalica, Z., Winkler, J., et al. (2015). Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications. *Clin Breast Cancer*, 15(6): 473-481.e3

Von Minckwitz, G, Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., et al. (2014). Neoadjuvant Carboplatin in Patients with Triple-Negative and HER2-Positive Early Breast Cancer (GeparSixto; GBG 66): A Randomised Phase 2 Trial. *Lancet Oncol*, 15(7):747–56.

Mittendorf, E. A., Philips, A. V., Meric-Bernstam, F., Qiao, N., Wu, Y., Harrington, S., et al. (2014, Apr). PD-L1 Expression in Triple Negative Breast Cancer. *Cancer Immunol Res*, 2(4): 361–370.

Morgan, S. E., & Kastan, M. B. (1997). p53 and ATM: cell cycle, cell death, and cancer. *Adv Cancer Res*, 71: 1-25.

Morris, G. J., Naidu, S., Topham, A. K., Guiles, F., Xu, Y., McCue, P., et al. (2007). Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients. *Cancer*, 110: 876–884.

Muenst, S., Schaerli, A., Gao, Däster, F., Trella, E., Droeser, R. A., Muraro, M. G., et al. (2014). Expression of Programmed Death Ligand 1 (PD-L1) Is Associated with Poor Prognosis in Human Breast Cancer. *Breast Cancer*

Res Treat, 146(1):15–24.

Nanda, R., Chow, L. Q., Dees, E. C., Berger, R., Gupta, S., Geva, R., *et al.* (2016, Jul). Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. *J Clin Oncol, 34(21): 2460-7.*

Nanda, R., Liu, M. C., Yau, C., Asare, S., Hylton, N., Van't Veer, L., *et al.* (2017, May). Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. *J Clin Oncol, 35(Suppl 15): abstract 506.*

Nuttal, F. Q., 2015. Body Mass Index: Obesity, BMI, and Health: A Critical Review. *Nutrition Today, 50(3)*, pp. 117-128.

Newman, L. A., Reis-Filho, J. S., Morrow, M., Carey, L. A., and King, T. A. (2015). The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: Triple-Negative Breast Cancer. *Ann Surg Oncol, 22(3):874–82.*

Nielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., *et al.* (2004). Immunohistochemical and Clinical Characterization of the Basal-like Subtype of Invasive Breast Carcinoma. *Clin Cancer Res, 10(16):5367–74.*

Niemeier, L. A., Dabbs, D. J., Beriwal, S., Striebel, J. M., & Bhargava, R. (2010, Feb). Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. *Mod Pathol, 23(2): 205-12.*

Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., *et al.* (2006, Jan). Epidermal growth factor receptor (EGFR) signaling in cancer. *Gene, 366(1): 2-16.*

Nguyen, P. L., Taghian, A. G., Katz, M. S., Niemierko, A., Abi Raad, R. F., Boon, W. L., *et al.* (2008). Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. *J Clin Oncol, 26(14): 2373-8.*

Ovcaricek, T., Frkovic, S. G., Matos, E., Mozina, B., dan Borstnar, S. (2011). Triple Negative Breast Cancer - Prognostic Factors and Survival. *Radiology and Oncology, 45(1):46–52.*

Pfirschke, C., Engblom, C., Rickelt, S., Cortez-Retamozo, V., Garris, C., Pucci, F., *et al.* (2016). Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. *Immunity, 44(2): 343–54.*

- Prat, A., Adamo, B., Cheang, M. C., Anders, C. K., Carey, L. A., & Perou, C. M. (2013). Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer. *The Oncologist, 18*: 123–133.
- Pan, Y., Yuan, Y., Liu, G., & Wei, Y. (2017). P53 and Ki-67 as prognostic markers in triple negative breast cancer patients. *PLoS ONE, 2*(2): e0172324.
- Park, S.M., Gaur, A.B., Lengyel, E., Peter, M.E.(2008). The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. *Genes Dev 283*(22):14910-4.
- Perou, C. M. (2010). Molecular Stratification of Triple-Negative Breast Cancers. *The Oncologist, 15*(S5):39–48.
- Petrelli, F., Coinu, A., Borgonovo, K., Cabiddu, M., Ghilardi, M., Lonati, V., dan Barni, S. (2014). The Value of Platinum Agents as Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers: A Systematic Review and Meta-Analysis. *Breast Cancer Res Treat, 144*(2):223–32.
- Piasecka, Dominika et al. 2018. “MicroRNAs in Regulation of Triple-Negative Breast Cancer Progression.” *Journal of Cancer Research and Clinical Oncology 144*(8): 1401–11.
- Pierobon, M. and Frankenfeld, C. L. (2013). Obesity as a Risk Factor for Triple-Negative Breast Cancers: A Systematic Review and Meta-Analysis. *Breast Cancer Res Treat, 137*(1):307–14.
- Pistelli, M., Pagliacci, A., Battelli, N., Santinelli, A., Biscotti, T., Ballatore, Z., et al. (2013). Prognostic Factors in Early-Stage Triple-Negative Breast Cancer: Lessons and Limits from Clinical Practice. *Anticancer Research, 33*(6):2737–42.
- Pinilla, S. M., Honrado, E., Hardisson, D., Benítez, J., & Palacios, J. (2006). Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. *Breast Cancer Res Treat, 99*(1): 85-90.
- Pinatel, E. M., Orso, F., Penna, E., Cimino, D., Elia, A. R., Circosta, P., et al. (2014). miR-223 Is a Coordinator of Breast Cancer Progression as Revealed by Bioinformatics Predictions. *PLoS One, 9*(1): e84859.
- Png, K. J., Halberg, N., Yoshida, M., & Tavazoie, S. F. (2011). A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. *Nature, 481*(7380): 190-4.
- Pogoda, K., Niwińska, A., Murawska, M., dan Pieńkowski, T. (2013). Analysis of Pattern, Time and Risk Factors Influencing Recurrence in Triple-Negative

Breast Cancer Patients. *Med Oncol*, 30(1):388.

Polivka, J. J., & Janku, F. (2014, May). Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. *Pharmacol Ther*, 142(2): 164-75.

Prat, A., Parker, J.S., Fan, C. dan Perou, C. M. (2012). PAM50 Assay and the Three-Gene Model for Identifying the Major and Clinically Relevant Molecular Subtypes of Breast Cancer. *Breast Cancer Res and Treat*, 135(1):301–6.

Qi, J. P., Yang, Y. L., Zhu, H., Wang, J., Jia, Y., Liu, N., *et al.* (2012, Dec). Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients. *Breast Cancer (Auckl)*, 6: 1-8.

Qian, B., Katsaros, D., Lu, L., Preti, M., Durando, A., Arisio, R., Mu, L., *et al.* (2009). High MiR-21 Expression in Breast Cancer Associated with Poor Disease-Free Survival in Early Stage Disease and High TGF-Beta1. *Breast Cancer Res and Treat*, 117(1):131–40.

Radojicic, J., Zaravinos, A., Vrekoussis, T., Kafousi, M., Spandidos, D. A., & Stathopoulos, E. N. (2011). MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. *Cell Cycle*, 10(3): 507-1.

Ren, Y. X., Hao, S., Jin, X., Ye, F. G., Gong, Y., Jiang, Y. Z., & Shao, Z. M. (2019). Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer. *Breast (Edinburgh, Scotland)*, 43: 97–104.

Ren, X., Wu, H., Lu, J., Zhang, Y., Luo, Y., Xu, Q., *et al.* (2018, Jan). PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer. *Cancer Biol Ther*, 16:1-8.

Richards, M. A., Westcombe, A. M., Love, S. B., Littlejohns, P., & Ramirez, A. J. (1999). Influence of delay on survival in patients with breast cancer: a systematic review. *Lancet*, 353: 1119-1126.

Richardson, L. C., Royalty, J., Howe, W., Helsel, W., Kammerer, W., & Bernard, V. B. (2010). Timeliness of Breast Cancer Diagnosis and Initiation of Treatment in the National Breast and Cervical Cancer Early Detection Program, 1996–2005. *Am J Public Health*, 100: 1769-177.

Ritter, A., Hirschfeld, M., Berner, K., Rucker, G., Jäger, M., Weiss, D., *et al.* 2020. Circulating Non-Coding RNA-Biomarker Potential in Neoadjuvant Chemotherapy of Triple Negative Breast Cancer? *International J Oncol* 56(1): 47–68.

- Rogers, T. J., Christenson, J. L., Greene, L. I., O'Neill, K. I., Williams, M. M., Gordon, M. A., *et al.* (2019). Reversal of Triple-Negative Breast Cancer EMT by MiR-200c Decreases Tryptophan Catabolism and a Program of Immunosuppression. *Molecul Cancer Res*, 17(1):30–41.
- Ruan, Q., Wang, P., Wang, T., Qi, J., Wei, M., Wang, S., Fan, T., *et al.* (2014). MicroRNA-21 Regulates T-Cell Apoptosis by Directly Targeting the Tumor Suppressor Gene Tipe2. *Cell Death and Disease*, 5(2).
- Sasaki, T., Hiroki, K., & Yamashita, Y. (2013, Aug). The Role of Epidermal Growth Factor Receptor in Cancer Metastasis and Microenvironment. *Biomed Res Int*, 2013: 546318.
- Safarudin, N. A. P. and Walta G. (2015). Pengaruh Indeks Massa Tubuh terhadap Disease-Free Survival Lima Tahun Pasien Kanker Payudara di Rumah Sakit Kanker “Dharmais” Jakarta. *Indonesian Journal of Cancer* 10 (1): 19-28.
- Schetter, A. J., Leung, S. Y., Sohn, J. J., Zanetti, K. A., Bowman, E. D., Yanaihara, N., *et al.* (2008). MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. *JAMA*, 299(4), 425–436. <https://doi.org/10.1001/jama.299.4.425>
- Schmid, P., Park, Y. H., Muñoz-Couselo, E., Kim, S. B., Sohn, J., & Im, S. A. (2017, May). Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173. *J Clin Oncol*, 35(suppl): abstract 556.
- Schooneveld, E. V., Wildiers, H., Vergote, I., Vermeulen, P. B., Dirix, L. Y., & Laere, S. J. (2015). Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. *Breast Cancer Res*, 17: 21.
- Seshacharyulu, P., Ponnusamy, M. P., Haridas, D., Jain, M., Ganti, A. K., & Batra, S. K. (2012, Jan). Targeting the EGFR signaling pathway in cancer therapy. *Expert Opin Ther Targets*, 16(1): 15–31.
- Sharpe, A. H., & Pauken, K. E. (2018, Mar). The diverse functions of the PD1 inhibitory pathway. *Nat Rev Immunol*, 18(3): 153-167.
- Shi, W., Hendrix, D., Levine, M., dan Haley, B. (2009). A Distinct Class of Small RNAs Arises from Pre-MiRNA-Proximal Regions in a Simple Chordate. *Nature Structural and Molecular Biology*, 16(2):183–89.
- Shu, D., Li, H., Shu, Y., Xiong, G., Carson, W. E., Haque, F., *et al.* (2015). Systemic Delivery of Anti-miRNA for Suppression of Triple Negative

Breast Cancer Utilizing RNA Nanotechnology. *ACS Nano*, 9(10): 9731-40.

Siddik, Z. H. (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. *Oncogene*, 22(47): 7265-79.

Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., *et al.* (2014). Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603. *J Clin Oncol*, 33: 13-21.

Sikov, W. M., Dizon, D. S., Strenger, R., Legare, R. D., Theall, K. P., Graves, T.A., Gass, J. S., *et al.* (2009). Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study. *J Clin Oncol*, 27(28):4693–4700.

Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szallasi, Z., Li, Q., *et al.* (2010). Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. *J Clin Oncol*, 28(7): 1145-53.

Skandan, S. P. (2016). 5 Year Overall Survival of Triple Negative Breast Cancer: A Single Institution Experience. *J Clin Oncol*, 34(15 suppl):e12580–e12580.

Smith, I. E., Jones, A. L., O'Brien, M. E., McKinna, J. A., Sacks, N., & Baum, M. (1993). Primary medical (neo-adjuvant) chemotherapy for operable breast cancer. *Eur J Cancer*, 29A(12): 1796-9.

Solzak, J. P., Atale, R. V., Hancock, B. A., Sinn, A. L., Pollok, K. E., Jones, D. R., & Radovich, M. (2017, Apr). Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer. *NPJ Breast Cancer*, 3: 17.

Sousa, G. F., Wlodarczyk, S. R., & Monteiro, G. (2014). Carboplatin: molecular mechanisms of action associated with chemoresistance. *Braz. J. Pharm. Sci*, 50(4).

Spitale, A., Mazzola, P., Soldini, D., Mazzucchelli, L., & Bordoni, A. (2009). Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. *Ann Oncol*, 20(4): 628-35.

Stockmans, G., Deraedt, K., Wildiers, H., Moerman, P., & Paridaens, R. (2008). Triple-negative breast cancer. *Curr Opin Oncol*, 20(6): 614-20.

Sun, Heng, Jing Zou, Ling Chen, Xuyu Zu, Gebo Wen, and Jing Zhong. 2017. Triple-Negative Breast Cancer and Its Association with Obesity (Review). *Molecular and Clinical Oncology* 7: 935-942.

Sun, X., Li, Y., Zheng, M., Zuo, W., & Zheng, W. (2016). MicroRNA-223 Increases the Sensitivity of Triple-Negative Breast Cancer Stem Cells to TRAIL-Induced Apoptosis by Targeting HAX-1. *PLoS One*, 11(9): e0162754.

Synnott, N. C., Murray, A. M., O'Donovan, N., *et al.* (2017). Combined treatment using the anti-p53 drug, APR-246 and eribulin: Synergistic growth inhibition in p53-mutated breast cancer cells. *J Clin Oncol*, 35(suppl 15): e14098.

Synnott, N. C., Murray, A. M., O'Donovan, N., *et al.* (2018). Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, APR-246. *Cancer Lett*, 414: 99-106.

Tan, G. H., Aib, N. A., Cho, W. Y., Teo, S. H., dan Yip, C. H. (2009). Clinical Characteristics of Triple-Negative Breast Cancer: Experience in an Asian Developing Country . *Asian Pac J Cancer Prev*, 10(3):395–98.

Telli, M. L., & Ford, J. M. (2010). Novel treatment approaches for triple-negative breast cancer. *Clin Breast Cancer*, 10 Suppl 1: E16-22.

Telli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., Szallasi, Z., Barry, W. T., Winer, E. P., Tung, N. M., Isakoff, S. J., Ryan, P. D., Greene-Colozzi, A., Gutin, A., Sangale, Z., Iliev, D., Neff, C., Abkevich, V., Jones, J. T., Lanchbury, J. S., ... Richardson, A. L. (2016). Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 22(15): 3764–3773.

The Cancer Genome Atlas Network. (2012). Comprehensive molecular portraits of human breast tumors. *Nature*, 490(7418): 61–70.

Thike, A. A., Cheok, P. Y., Jara-Lazaro, A. R., Tan, B., Tan, P., & Tan, P. H. (2010). Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. *Mod Pathol*, 23(1): 123-33.

Thike, A. A., Iqbal, J., Cheok, P. Y., Chong, A. P. Y., Tse, G. M. K., Tan, B., Tan, P., Wong, N. S., and Tan, P. H. (2010). Triple Negative Breast Cancer: Outcome Correlation with Immunohistochemical Detection of Basal Markers. *American J Surg Pathol*, 34(7):956–64.

Thike, A. A., Yong-Zheng Chong, L., Cheok, P. Y., Li, H. H., Wai-Cheong Yip, G., Huat Bay, B., *et al.* (2014, Mar). Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer. *Mod Pathol*, 27(3): 352-60.

Tian, T., Li, X., & Zhang, J. (2019). mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy. *International journal of molecular sciences*, 20(3): 755.

Toss, A., & Cristofanilli, M. (2015). Molecular characterization and targeted therapeutic approaches in breast cancer. *Breast Cancer Res*, 17: 60.

Tomioka, N., Azuma, M., Ikarashi, M., Yamamoto, M., Sato, M., Watanabe, K. I., *et al.* (2018, Jan). The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). *Breast Cancer*, 25(1): 34-42.

Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S., O'Shaughnessy, J., *et al.* (2018, Jan). Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. *J Clin Oncol*, JCO2016713495.

Tubiana-Hulin, M., Malek, M., Brifford, M., *et al.* (1993). Preoperative chemotherapy of operable breast cancer (stage IIIA). Prognostic factors of distant recurrence. *Eur J Cancer*, 29A: S76 (#391).

Tung, N. M., and Eric, P. Winer. (2015). Tumor-Infiltrating Lymphocytes and Response to Platinum in Triple-Negative Breast Cancer. *J Clin Oncol*, 33(9): 969-71.

Ueng, S., Chen, S., Chang, Y., Hsueh, S., Lin, Y., Chien, H., Lo, Y., *et al.* (2012). Phosphorylated MTOR Expression Correlates With Poor Outcome in Early-Stage Triple Negative Breast Carcinomas. *Int J Clin Exp Pathol*, 5(8):806-13.

Uhlmann, S., Zhang, J., Schwäger, A., Mannsperger, H., Riazalhosseini, Y., Burmester, S., Ward, A., Korf, U., Wiemann, S., Sahin, O. (2010). miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. *Oncogene*; 29(30):4297-306

Voduc, K. D., Cheang, M. C., Tyldesley, S., Gelmon, K., Nielsen, T. O., & Kennecke, H. (2010). Breast cancer subtypes and the risk of local and regional relapse. *J Clin Oncol*, 28(10): 1684-91.

Volinia, S., Calin, G. A., Liu, C. G., Ambs, S., Cimmino, A., Petrocca, F., *et al.* (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc Natl Acad Sci U S A*, 103(7): 2257-61.

Vona-Davis, L., Rose, D. P., Hazard, H., Howard-McNatt, M., Adkins, F., Partin, J., and Hobbs, G. (2008). Triple-Negative Breast Cancer and Obesity in a Rural Appalachian Population. *Cancer Epidemiol Biomarkers Prev*, 17(12):3319–24.

Wahidin, M., Noviani, R., Hermawan, S., Andriani, V., Ardian, A., & Djarir, H. (2012). Population-Based Cancer Registration in Indonesia. *Asian Pacific J Cancer Prev*, 13(4): 1709-1710.

Walerych, D., Lisek, K., and Sal, G.D. (2015). Mutant P53: One, No One, and One Hundred Thousand. *Frontiers in Oncology*, 5.

Walerych, D., Napoli, M., Collavin, L., & Del Sal, G. (2012). The rebel angel: mutant p53 as the driving oncogene in breast cancer. *Carcinogenesis*, 33(11): 2007-17.

Wang, R. X., Chen, S., Jin, X., & Shao, Z. M. (2016). Value of Ki-67 expression in triple negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin. *Sci. Rep*, 6: 30091.
Wang, P., Liu, X. M., Ding, L., Zhang, X. J., & Ma, Z. L. (2018). mTOR signaling-related MicroRNAs and Cancer involvement. *Journal of Cancer*, 9(4): 667–673.

Wang, H., Tan, Z., Hu, H., Liu, H., Wu, T., Zheng, C., Wang, X., Luo, Z., Wang, J., Liu, S., Lu, Z., & Tu, J. (2019). microRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1. *BMC cancer*, 19(1): 738

Wang, W., Wu, J., Zhang, P., Fei, X., Zong, Y., Chen, X., *et al.* (2016). Prognostic and predictive value of Ki-67 in triple-negative breast cancer. *Oncotarget*, 7(21): 31079-87.

Wang, F., Zhang, L., Xu, H., Li, R., Xu, L., Qin, Z., dan Zhong, B. (2019). The Significance Role of MicroRNA-200c as a Prognostic Factor in Various Human Solid Malignant Neoplasms: A Meta-Analysis. *J Cancer*, 10(1):277–86.

Wang, Q., Zhao, D. Y., Xu, H., Zhou, H., Yang, Q. Y., Liu, F., & Zhou, G. P. (2015). Down-regulation of microRNA-223 promotes degranulation via the PI3K/Akt pathway by targeting IGF-1R in mast cells. *PloS one*, 10(4), e0123575.

Wang, J., Zhu, X., Xu, X., Guo, L., Shen, G., Liu, X., Chang, C., Wang, B., *et al.* (2017). PIK3CA Mutations and Downstream Effector P-MTOR Expression: Implication for Prognostic Factors and Therapeutic Targets in Triple Negative Breast Cancer. *Int J Clin Exp Pathol*, 10(7):7682.

Wang, X., and Yueping, Liu. (2020). PD-L1 Expression in Tumor Infiltrated Lymphocytes Predicts Survival in Triple-Negative Breast Cancer. *Pathol Res Practice*, 216(3).

West, N. R. Milne, K., Truong, P. T., Macpherson, N., Nelson, B. H., Watson, P. H., *et al.* (2011). Tumor-Infiltrating Lymphocytes Predict Response to Anthracycline-Based Chemotherapy in Estrogen Receptor-Negative Breast Cancer. *Breast Cancer Research*, 13(6).

Widodo, I., Dwianingsih, E. K., Triningsih, E., Utoro, T., dan Soeripto. (2014). Clinicopathological Features of Indonesian Breast Cancers with Different Molecular Subtypes. *Asian Pac J Cancer Prev*, 15(15):6109–13.

Wolmark, N., Wang, J., Mamounas, E., Bryant, J., & Fisher, B. (2001). Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. *J Natl Cancer Inst Monogr*, (30): 96-102.

Wong, K. Y., Yu, L., dan Chim, C. S. (2011). DNA Methylation of Tumor Suppressor MiRNA Genes: A Lesson from the *MiR-34* Family. *Epigenomics*, 3(1):83–92.

Woo, S. U., Sangai, T., Akcakanat, A., Chen, H., Wei, C., & Meric-Bernstam, F. (2017, Oct). Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer. *Oncogenesis*, 6(10): e385.

Yagata, H., Kajiura, Y., & Yamauchi, H. (2011). Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy. *Breast Cancer*, 18(3): 165-73.

Yan, L. X., Huang, X. F., Shao, Q., Huang, M. Y., Deng, L., Wu, Q. L., Zeng, Y. X., & Shao, J. Y. (2008). MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. *RNA (New York, N.Y.)*, 14(11): 2348–2360

- Yang, F., Zhang, W., Shen, Y., & Guan, X. (2015, Mar). Identification of dysregulated microRNAs in triple-negative breast cancer (review). *Int J Oncol*, 46(3): 927-32.
- Yang, X. R., Chang-Claude, J., Goode, E. L., Couch, F. J., Nevanlinna, H., Milne, R. L., *et al.* (2011). Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. *J Natl Cancer Inst*, 103(3): 250-63.
- Yang, Y., Jiang, Z., Ma, N., Wang, B., Liu, J., Zhang, L., & Gu, L. (2018). MicroRNA-223 Targeting STIM1 Inhibits the Biological Behavior of Breast Cancer. *Cell Physiol Biochem*, 45(2): 856-66.
- Yeh, J., Chun, J., Schwartz, S., dan Wang A. (2017). Clinical Characteristics in Patients with Triple Negative Breast Cancer. *Int J Breast Cancer*, 1796145.
- Yoo, T. K., Han, W., Moo, H. G., Kim, J., Lee, J. W., Kim, M. K., *et al.* (2016). Delay of Treatment Initiation Does Not Adversely Affect Survival Outcome in Breast Cancer. *Cancer Res Treat*, 48(3): 962–969.
- Yoon, C. I., Park, S., Cha, Y. J., Lee, H. S., Bae, S. J., Cha, C., *et al.* (2020). Associations between Absolute Neutrophil Count and Lymphocyte-Predominant Breast Cancer. *Breast*, 50:141–48.
- Yousefi K., Shahram, A., Yazdanfar, S., Akbari, M. E., dan Rakhsha, A. (2017). Triple Negative Breast Cancer in Iranian Women: Clinical Profile and Survival Study. *Int J Cancer Management*, 10(8).
- Yue, Y., Astvatsaturyan, K., Cui, X., Zhang, X., Fraass, B., & Bose, S. (2016, Mar). Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers. *PLoS One*, 11(3): e0149661.
- Yue, Y., Astvatsaturyan, K., Cui, X., Zhang, X., Fraass, B., & Bose, S. (2016, Mar). Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers. *PLoS One*, 11(3): e0149661.
- Zaravinos, A. (2015). The Regulatory Role of MicroRNAs in EMT and Cancer. *J Oncol* 2015():865816.
- Zhan, Q. H., Fu, J. Q., Fu, F. M., Zhang, J., and Wang, C. (2018). Survival and Time to Initiation of Adjuvant Chemotherapy among Breast Cancer Patients: A Systematic Review and Meta-Analysis. *Oncotarget*, 9(2):2739–51.
- Zhang, Y., Kwok-Shing Ng, P., Kucherlapati, M., Chen, F., Liu, Y., Tsang, Y. H., *et al.* (2017, Jun). A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. *Cancer Cell*, 31(6): 820-832.e3.

- Zhang, B., Pan, X., Cobb, G. P., & Anderson, T. A. (2007). microRNAs as oncogenes and tumor suppressors. *Dev Biol*, 302(1): 1-12.
- Zhang, M., Sun, H., Zhao, S., Wang, Y., Pu, H., dan Zhang, Q. (2017). Expression of PD-L1 and Prognosis in Breast Cancer: A Metaanalysis. *Oncotarget*, 8(19):31347-54.
- Zhu, S., Wu, H., Wu, F., Nie, D., Sheng, S., & Mo, Y. Y. (2008). MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. *Cell Res*, 18: 350-9.